Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Losartan vs MitoQ: MitoQ has the stronger overall evidence (5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
MitoQ wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Losartan and MitoQ have evidence — compare verdict strength side-by-side.
Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored.
Any time of day
Oral tablet (losartan potassium)
10-20mg daily
Morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
Possible additive vascular/BP effects given the endothelial-function mechanism; monitor.
Discuss with your healthcare provider before combining.
Months to years
Years
Unknown in humans
Throughout use
Acute to 6 weeks
4 weeks
12 months
3 weeks
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet (London, England) (2002) · Rct · n=9193
LIFE randomized trial in hypertensives with left-ventricular hypertrophy
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine (2001) · Rct · n=1513
RENAAL randomized, double-blind trial in type-2 diabetic nephropathy
Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.
Science translational medicine (2011) · Animal
In sarcopenic mice, losartan reduced fibrosis and improved muscle function after injury
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
MitoQ has a higher evidence score (5/10 vs 4.2/10) and wins in 2 of 3 categories.
For support heart health, Losartan has a higher relevance score (66 vs 60).
Possible additive vascular/BP effects given the endothelial-function mechanism; monitor. Discuss with your healthcare provider before combining. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.